DDR gene mutations associated with complete response to chemo in bladder cancer

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

Stephen BaylinAndrew FeinbergJohns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center researchers Stephen Baylin and Andrew Feinberg were awarded the 2022–2023 Harvey Prize in the field of Science and Technology by the Technion—Israel Institute of Technology.

December 13, 2024

Vol.50 No.46

Clinical Roundup

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Genetic disposition increases the risk of breast cancer metastasis

For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Genetic mutations accumulate in smokers with MDS, study shows

Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.

December 13, 2024

Vol.50 No.46

Clinical Roundup

High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows

Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Study identifies that higher West African ancestry may contribute to worse outcomes

A study published in JAMA Network Open underscored the importance of utilizing genetic ancestry beyond self-reported race in prognosticating breast cancer outcomes for Black women and addressing their disproportionately higher mortality rate.

December 13, 2024

Vol.50 No.46

DDR gene mutations associated with complete response to chemo in bladder cancer

YOU MAY BE INTERESTED IN

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Genetic disposition increases the risk of breast cancer metastasis

Genetic mutations accumulate in smokers with MDS, study shows

High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows

Study identifies that higher West African ancestry may contribute to worse outcomes

Renew today!

Subscriber content

Never miss an issue!

Login